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Background: HVR1 spans 27 residues at the N terminus of the HCV envelope glycoprotein E2 and is the most variable
region within the HCV polyprotein.
Results: Three independent functional microdomains were identified in HCV HVR1.
Conclusion: Different microdomains in HVR1 cooperate to mediate HCV cell entry and immune evasion.
Significance: The data provide novel insights into understanding the mechanisms of HCV infection and immune evasion.
High genetic heterogeneity is an important characteristic of
hepatitis C virus (HCV) that contributes to its ability to establish
persistent infection. The hypervariable region 1 (HVR1) that
includes the first 27 amino acid residues of the E2 envelope gly-
coprotein is the most variable region within the HCV polypro-
tein. HVR1 plays a major role in both HCV cell entry and
immune evasion, but the respective contribution of specific
amino acid residues is still unclear. Ourmutagenesis analyses of
HCV pseudoparticles and cell culture-derived HCV using the
H77 isolate indicate that five residues at positions 14, 15, and
25–27mediate binding of the E2 protein to the scavenger recep-
tor class B, type I receptor, and any residue herein is indispen-
sable for HCV cell entry. The region spanning positions 16–24
contains the sole neutralizing epitope and is dispensable for
HCV entry, but it is involved in heparan binding. More impor-
tantly, this region is necessary for the enhancement of HCV
entry by high density lipoprotein and interferes with virus neu-
tralization by E2-neutralizing antibodies. Residues at positions
1–13 are also dispensable for HCV entry, but they can affect
HCV infectivity by modulating binding of the envelope protein
to scavenger receptor class B, type I.Mutations occurring at this
site may confer resistance to HVR1 antibodies. These findings
further our understanding about the mechanisms of HCV cell
entry and the significance of HVR1 variation in HCV immune
evasion. They have major implications for the development of
HCV entry inhibitors and prophylactic vaccines.
Hepatitis C virus (HCV)6 is an enveloped single-stranded
positive-sense RNA virus in the Flaviviridae family that infects
more than 180 million individuals worldwide (1) and is a major
cause of chronic liver disease, cirrhosis, and hepatocellular car-
cinoma (2). HCV infection is the most common indication for
liver transplantation in developed countries (3). Antiviral treat-
ment is limited by resistance and adverse effects, and a vaccine
is not currently available (4). Patients with acute HCV infection
are generally asymptomatic, and 75–85% of the HCV-in-
fected persons progress toward chronic infection (5). HCV has
evolved highly successful mechanisms for evading host
immune responses, among which mutation is an important
strategy that contributes to the development of chronic infec-
tion (6–8). Indeed, HCV has a high mutation rate that results
from an error-prone RNA polymerase that yields genetically
heterogeneous quasispecies that are characteristic of most
infections (9, 10). These sequence variations are concentrated
in specific regions of the genome, and the best characterized
hypervariable region is the 27-amino acid residue component
located at the N-terminal part of the envelope protein E2
(hypervariable region 1 (HVR1)) (11–13). HVR1 contains dom-
inant neutralizing epitopes, and its variation may lead to virus
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escape from pre-existing neutralizing antibodies (14–18).
Mutation of HVR1 has been proposed to be driven by immune
pressure and to play an important role in the establishment of
persistent infection and disease progression (19–21).
HCV cell entry involves the initial attachment of the virus
onto the cell surface through interaction of the virion envelope
and associated low density lipoproteins (LDL) with cell surface
glycosaminoglycans (such as heparan sulfate) (22, 23) and the
LDL receptor (LDLr) (24, 25). This is followed by more specific
interaction with several cellular surface molecules as follows:
scavenger receptor class B, type I (SR-BI) (26–28); CD81 (29);
Claudin 1 (CLDN1) (30), and occludin (OCLN) (31). SR-BI, a
major receptor of high density lipoprotein (HDL), is a key host
factor for HCV infection that is required for an entry step (26–
28). HVR1 is responsible for the interaction between the HCV
envelope glycoproteins and SR-BI and plays an important role
in HCV cell entry (26, 32, 33), but it is dispensable for RNA
replication, virion assembly, and release (34). In line with this
interpretation, removal of HVR1markedly decreased the infec-
tivity of HCV pseudoparticles (HCVpp) and cell culture-pro-
duced HCV (HCVcc) (32, 35), and an HCV mutant lacking
HVR1was shown to be infectious in chimpanzees, but its infec-
tivity was significantly attenuated (36). Two recent reports have
shown that HVR1 is critical for the infectivity of low density
HCV particles (34, 37). Moreover, human HDL enhances HCV
infection and protects HCV against neutralizing antibodies via
its interplay withHVR1 and SR-BI, which further highlights the
importance of HVR1 in theHCV life cycle (33, 38–40). In addi-
tion,HVR1 is involved in the binding ofHCVenvelope proteins
to cell surface glycosaminoglycans, and it facilitates viral parti-
cle-host cell interaction (23, 24). AlthoughHVR1 is highly vari-
able, its importance in virus entry suggests that structural con-
straints might be present within this region. In this context, it
has been suggested that the variability of HVR1 is not random,
as its chemical and physical properties and its conformation are
conserved (41, 42). Despite these observations, the relationship
between the HVR1 structure and its function remains to be
defined.
HCVpp bearing functional envelope proteins represents a
valid model for the study of HCV cell entry and antibody-me-
diated neutralization (43, 44). Using thismodel, we investigated
the functional role of amino acid stretches or single residues
within the HVR1 domain of the HCV H77 isolate in cell entry
and antibody-mediated neutralization, and we confirmed the
findings by using theHCVccmodel system. Our data show that
HCV HVR1 contains three different functional microdomains
that cooperate to confer HCV cell entry and immune evasion.
EXPERIMENTAL PROCEDURES
Preparation of Rabbit and Mouse Antibodies to HVR1—The
DNA sequences encoding the 27 residues of HVR1 of the H77
isolate (1a genotype), aa 1–13 (N13), aa 8–20 (M13), and aa
14–27 (C14) of H77HVR1, or the 27 residues of HVR1 of Con1
isolate (1b genotype) were fused to the 3 terminus of the thi-
oredoxin (TRX) gene in the vector pET32a (Novagen,Madison,
WI). Protein expression and antibody preparation were as we
described recently (45). Briefly, the TRX and HVR1 peptide
fusion proteins were expressed using Escherichia coli BL21/
DE3 under induction by isopropyl -D-thiogalactopyranoside
and purified using nickel-chelating Sepharose resin (Qiagen,
Hilden, Germany). The proteins were emulsified with Freund’s
adjuvant (Sigma) and used to immunize New Zealand White
rabbits for a total of four times over a 2-week interval. Sera were
collected 1 week after the last immunization. Total IgG was
purified using protein A resin (GE Healthcare).
The DNA sequence encoding H77 HVR1 was spliced to the
5- or 3-terminal of the HBsAg gene. The resulting fusion
genes HVR1-HBsAg and HBsAg-HVR1 were inserted into the
pcDNA3.1 vector (Invitrogen), respectively, and then the
expression plasmids were used to immunize BALB/c mice (50
g/mouse) by intramuscular injection for a total of three times
at a 2-week interval. Sera were collected at 2 weeks after the
third immunization, and their binding to H77 envelope pro-
teins was assayed by ELISA. The procedures used in the han-
dling and care of the animals were approved by the Animal
Ethical Committee of the Second Military Medical University,
Shanghai, China.
Plasmid Constructs—The plasmid phCMV-E1E2 carrying
the HCV E1E2 sequence of the H77 isolate was kindly provided
by Cosset and co-workers (43). This plasmid was used as a tem-
plate to prepare HVR1 deletion mutants using standard fusion
PCR, followed by insertion into phCMV vector. The plasmid
containing full-length cDNA of the Con1 isolate was kindly
provided by Rice and co-workers (46). This plasmidwas used as
a template to amplify the E1E2 sequence by PCR, and the E1E2
sequenceswithHVR1deletionmutations using fusion PCR and
the resulting fragments were inserted into the phCMV vector.
The 77-Con1 chimeric E1E2 expression plasmid was con-
structed by replacement of the HVR1 16–24-aa encoding
sequence in the context of the H77 E1E2 backbone with corre-
sponding sequence in HVR1 of Con1 isolate using fusion PCR.
Similarly, Con1-H77 plasmid was constructed by replacement
of the HVR1 16–24-aa sequence in the Con1 envelope back-
bone for that of H77 HVR1. HJ3/QL H77/JFH1 chimeric
genome was kindly provided by Lemon and co-workers (47).
HVR1 deletion mutants were generated by deleting the indi-
cated sequences in the genomic cDNA backbone using fusion
PCR together with endonuclease digestion and ligation. All the
envelope encoding sequences were confirmed by DNA
sequencing.
Generation, Infection, and Neutralization of HCVpp—
HCVpp was generated as described (45, 48). Briefly, HEK 293T
cells were co-transfected with expression plasmids encoding
HCV envelope glycoproteins, Gag/Pol (pLP1), Rev (pLP2) and
the transfer vector, pLenti6 (Invitrogen) containing the green
fluorescent protein (GFP) gene. Cell culture supernatants con-
taining pseudoparticles were harvested at 48 h after transfec-
tion and filtered through 0.45-m membranes. To confirm
incorporation of HCV envelope glycoproteins into pseu-
dotyped particles, pseudoparticles in cell culture supernatants
were pelleted by centrifugation through a 20% sucrose cushion
and examined for the E1, E2, andHIVGag proteins byWestern
blot assay as described previously (42). Briefly, proteins sepa-
rated by SDS-PAGEwere electrotransferred ontoHybond-ECL
nitrocellulose membranes (Amersham Biosciences) and
probedwith the appropriate antibodies (E1mAbA4 clone, goat
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anti-E2 pAb and HIV Gag mAb). HCV E1 mAb A4 was
described previously (42). Goat anti-E2 pAb was purchased
from Biodesign International (Memphis, TN). Anti-HIV Gag
mAb was obtained from Wantai Biological Pharmacy (Beijing,
China). The immunoreactive bands were visualized using horse-
radish peroxidase (HRP)-conjugated anti-goat or mouse IgG
(Sigma) followed by enhanced chemiluminescence (Pierce).
Target Huh7.5 cells (kindly provided by C. M. Rice) were
seeded into 96-well plates at a density of 8 103 cells/well and
incubated overnight at 37 °C. HCVpp normalized to equal
quantities of HCVE2 andHIVGag proteins were added to each
well, incubated for 5 h, and removed. The cells were further
incubated in regular medium at 37 °C for 72 h. HCVpp entry
into Huh7.5 cells was analyzed by flow cytometry (43). In indi-
cated cases, the medium containing HCVpp was added to
Huh7.5 cell cultures together with HDL (Calbiochem) at a con-
centration of 6g/ml, and the supernatants were replaced with
regular medium 5 h later as described previously (33, 38, 39).
For neutralization assay, HCVpp supernatants were preincu-
bated with total IgG purified from rabbit immune sera or anti-
HCV E2 mAb H48 (49) or IgG purified from sera of HCV-
infected individuals by fractionation on protein A/G columns
(30 min at 37 °C) prior to infection of Huh7.5 cells. Pseudopar-
ticles generated with VSV-G glycoprotein (VSV-GP) (Invitro-
gen) were used as control.
E2 Binding to Human SR-BI and CD81—Lentivirus vectors
for human SR-BI or CD81 and mouse immune sera against
human SR-BI were prepared as described (45). CHO cells were
infected with the SR-BI or CD-81 vectors using the empty len-
tivirus vector as control, and SR-BI and CD81 expression was
confirmed by FACS using mouse immune sera against SR-BI
and anti-CD81 mAb clone JS81 (BD Biosciences), respectively.
HEK 293T cells were transfected with prototype E1E2 or a
panel of mutant E1E2 expression plasmids or the empty vector,
and 72 h later the cells were detached from the dishes in phos-
phate-buffered saline (PBS)/EDTA, centrifuged, resuspended
in PBS supplemented with a proteinase inhibitor mixture
(Roche Applied Science), and lysed by ultrasonication. The cell
lysates were centrifuged, and the supernatants were concen-
trated 5-fold using a Centricon ultrafiltration tube (Millipore,
Bedford, MA). E2 protein in crude cell extract was normalized
using Galanthus nivalis agglutinin (GNA) capture ELISA with
conformation-dependent anti-E2 mAb H53 or H48 as
described (50, 51).
The binding of normalized envelope protein to cell surface-
associated SR-BI or CD81 was determined using a FACS-based
assay as described previously (45, 52). Briefly, 4 105CHOcells
expressing human SR-BI or CD81 or transfected with the
empty vector were incubated with crude cell extract that con-
tained equivalent amounts of E2 protein for 1 h at room tem-
perature (RT), washed twice, and incubated with anti-E2 mAb
H53 (1 h at RT). After labelingwithAlexa Fluor 488-conjugated
goat anti-mouse IgG (Invitrogen), themean fluorescence inten-
sity (MFI) was quantified by a flow cytometry (Cell Lab
QuantaTM SC Instrument, Beckman Coulter, Fullerton, CA).
Background MFI was defined as E2 binding to CHO cells
infected with empty vector and subtracted from theMFI values
for the mutant and prototype E2 binding to SR-BI or CD81-
expressing cells. The binding activity of each mutant envelope
protein was expressed as the percentages of subtracted MFI
relative to the MFI of H77 prototype envelope protein. The
extract from 293T cells given the empty vector (containing
equivalent amounts of total cellular protein) was used as con-
trol to probe the potential binding of 293T cell-derived proteins
with SR-BI or CD81.
Envelope Protein Binding to HVR1 Antibodies—The binding
of envelope proteins to HVR1 antibodies was assayed by GNA
capture ELISA as described previously (50, 51). In brief, ELISA
plates were coated with GNA (Sigma) and incubated overnight
at 4 °C. The plates were washed with PBS containing 0.05%
Tween 20 (PBST), and nonspecific binding sites were saturated
with blocking buffer (3% BSA and 0.05%Tween 20 in PBS). The
lysates of HEK 293T cells transfected with vectors expressing
the various mutant HCV envelope proteins or empty vector
were added to the plates and incubated at RT for 2 h. After
extensive washing, rabbit anti-HVR1 IgG (20–500 g/ml) and
sera collected from mice immunized with HBsAg and HVR1
fusion gene expression plasmids or anti-E2 mAb H53 (1:1000)
were added at RT for 40min. The plates were washed and incu-
bated (40 min at RT) with horseradish peroxidase-conjugated
goat anti-rabbit or goat anti-mouse IgG (diluted 1:2,000). Then
the plates were washed, and color was developed using
3,3,5,5-tetramethylbenzidine as the substrate. The absorb-
ance at 450 nm wavelength was measured.
Envelope Protein-Heparan Interaction—The binding ofHCV
envelope protein to heparan and inhibition of envelope-hepa-
ran binding by HVR1 antibodies was assayed as described pre-
viously (22, 23). Briefly, 96-well ELISA plates were coated with
sulfated heparan (Merck) in PBS (1 g/well) and incubated
overnight at 4 °C. They were blocked with blocking buffer (3%
BSA and 0.05% Tween 20 in PBS) (1 h at RT). Cell extracts
containing equal quantities of HCV envelope protein were pre-
incubated (1 h at RT) with different concentrations of IgG frac-
tionated from sera collected from rabbits immunized with
TRX-HVR1 fusion protein. Subsequently, envelope protein-
antibody complexes were added to the wells precoated with
heparan and incubated for 1 h at 37 °C. After washing, heparan-
bound envelope protein was detected by the addition of anti-E2
mAb H53 and horseradish peroxidase-conjugated goat anti-
mouse IgG. Protein-bound antibodies were detected by color-
imetry as described above.
Production, Infection, and Neutralization of HCVcc—The
generation of H77/JFH1 chimeric HCVccwas as described pre-
viously (35, 53, 54). Briefly, the plasmids harboring chimeric
genomic cDNA were linearized and used as transcription tem-
plates with an in vitro MEGAscript kit (Promega, Madison,
WI). CD81-deficient Huh7 cells were kindly provided by Dr. J.
Zhong (Institut Pasteur of Shanghai, Chinese Academy of Sci-
ences, Shanghai, China) (55). The in vitro-transcribed RNAwas
delivered to Huh7.5 cells or CD81-deficient Huh7 cells by elec-
troporation. HCV core protein in transfected Huh7.5 or Huh7
cells and the respective culture supernatants were determined
using a commercial ELISA kit according to the manufacturer’s
instructions (Kangyun, Yueyang, China). Culture supernatants
fromHuh7.5 cells were collected on day 5 after transfection and
were used to infect Huh7.5 cells in the absence or presence of
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HDL (6 g/ml). After 2 days, HCVcc-infected cells were exam-
ined for NS5A expression by immunofluorescent staining with
mAb 9E10 (53). Stained foci were counted in quadruplicate
wells, and virus titers are expressed as foci forming units (FFU)/
ml. HCVcc neutralization was assayed as described previously
(56, 57). Briefly, normalized HCVcc were preincubated (37 °C
for 1 h) with the total IgG fraction from sera collected from
rabbits immunized with TRX-HVR1 fusion protein or E2 mAb
H48 at the indicated concentrations and added to Huh7.5 cells
in 96-well plates. After 2 days, the cells were immunostained for
NS5A, and the results were expressed as percent neutralization
calculated as themean percentages of infectious titer inhibition
relative to incubation with medium devoid of antibody.
Statistical Analysis—Data are expressed asmeans S.D. Sta-
tistical significance is analyzed by the Student’s t test. p values
below 5% are considered significant.
RESULTS
HVR1 Residues at Positions 14, 15, and 25–27 Are Required
forH77HCVppCell Entry (Five Key Residues)—Apanel of E1E2
expression plasmids containing deletion mutations within the
HVR1 of HCV H77 isolate were constructed and used to pre-
pareHCVpseudoparticles by co-transfection of 293T cells with
lentivirus capsid and transfer plasmids. The amino acid
sequence of HVR1 is shown in Fig. 1A. GNA capture ELISA of
the expression products from 293T cells transfected with the
prototype or mutant envelope plasmids using anti-E2 poly-
clonal antibodies and conformation-dependent E2 mAb H53
and H48 indicated that none of the single residue deletions
affected E2 protein expression or conformation (data not
shown).Western blotting of purified pseudoparticles in the cell
supernatants showed that none of the deletions affected the
HCV envelope proteins incorporated into pseudoparticles (Fig.
1B). Examination of the infectivity of the corresponding pseu-
doparticles in Huh7.5 cells indicated that HCVpp infectivity
was decreased to less than 5% of the unmodified pseudopar-
ticles by deletion of the entire HVR1 (HVR1) and deletion of a
single residue at positions 14, 15, 25, 26, or 27 reduced the
infectivity bymore than 85%. By contrast, deletion of any single
residue within position 1–13 or 16–24 only moderately
affected the pseudoparticle infectivity (Fig. 1C).
Regions Spanning HVR1 Amino Acids 1–13 and 16–24 Are
Not Necessary for HCVpp Infection, but the Latter Stretch Is
Necessary for Infection Enhancement by HDL—Having seen
that deletion of any residue in aa stretches 1–13 and 16–24 did
not attenuate HCVpp infectivity, we wanted to better under-
stand the relevance of these regions with respect to HCVpp
infectivity. Deletion of either one of the two stretches did not
affect the binding of conformation-dependent mAb H53 and
H48 clones to E2 protein (data not shown) nor pseudoparticle
production (Fig. 2B). When infection was done in the absence
of humanHDL, deletion of the residues across aa 1–13 (1–13)
reduced HCVpp infectivity by about 20%. Interestingly, dele-
tion of nine residues across aa 16–24 (16–24) did not reduce
HCVpp infectivity, but instead it increased the infectivity by up
to 40% (Fig. 2A). Pseudoparticles bearing HCV envelope pro-
teins with deletion of both aa 1–13 and 16–24 in HVR1 (five
FIGURE 1. Residues at positions 14, 15, and 25–27 in HVR1 are indispensable for HCVpp cell entry. A, amino acid sequence of the H77 isolate HVR1 used
for functional microdomain identification. B, HEK 293T cells were transfected with lentivirus vectors containing the GFP reporter gene, HIV capsid (Gag/Pol)
plasmid, Rev plasmid, and HCV envelope protein (H77 isolate) expression plasmids harboring single residue deletion in HVR1. Co-transfection of 293T cells
devoid of HCV envelope protein (env) plasmid was performed as a negative control. Forty eight hours later, pseudoparticles in the culture media were
pelleted through 20% sucrose cushions and analyzed by Western blotting. HCV envelope proteins and HIV Gag protein were probed with goat anti-E2 pAb,
anti-E1 mAb (A4), and anti-HIV Gag (anti-Gag) mAb, respectively. Results are shown for one representative experiment out of three independent assays. C,
plasmids encoding different deletionmutants of HVR1 in the context of a full-length E1E2 glycoproteinwere used to generate HCVpp. Co-transfection of 293T
cells devoid of the HCV envelope protein (env) plasmid was performed as a negative control. Pseudoparticles normalized to equal quantities of HCV E2 and
HIV Gag proteins were used to infect Huh7.5 target cells, and HCVpp cell entry was determined 3 days later by quantification of GFP-positive cells by flow
cytometry. The infectivity of H77 prototype pseudoparticles was6 104 FFU/ml, the infectivity of pseudoparticles with mutation in HVR1 is expressed as
percentage of the infectivity of H77 prototype. Data are the means of four independent experiments S.D.
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key, containing only the five residues at position 14, 15, and
25–27) retained the infectivity by about 34% (Fig. 2A).Mutation
of alanine at position 14 to glycine and alanine scanning
mutagenesis of residues 15 and 25–27 reduced pseudoparticle
infectivity by less than 30%, and the combined mutations of
both aa 14 and 15 (A14G/G15A) or aa 25–27 (C3A, all of the
three residues were replacedwith alanine) decreased the infectiv-
ity by about 60 and 75%, respectively, indicating that residues at
these positions cooperate tomediate HCV cell entry, and they are
not specifically selected during viral evolution (Fig. 2C).
HVR1 acts as an essential viral component that modulates
HDL-mediated enhancement of HCV infection (38–40). To
identify the potential regions involved in this function, we
examined the effect of HDL on the infectivity of these pseudop-
articles. As shown in Fig. 2A, the enhancement ofHCVpp infec-
tivity by HDL is dependent on the presence of the 16–24-aa
stretch.
Previous studies have indicated that HVR1 plays an impor-
tant role in modulating E2 binding to SR-BI and CD81 (26, 58).
To investigate the role of the identified amino acid stretches in
the interaction with SR-BI and CD81, we assessed the binding
of the mutant envelope proteins to CHO cells that express
human SR-BI orCD81 (Fig. 2D). The infectivity of the pseudop-
articles positively correlated with the SR-BI binding activity of
the corresponding envelope proteins (Fig. 2E). A single deletion
within aa 14, 15, and 25–27 reduced SR-BI binding activity by
more than 85%, whereas a single point substitution mutation
within these five residues or deletion of aa 1–13 reduced SR-BI
binding activity by less than 25% (Fig. 2E). Furthermore, dele-
tion of aa 16–24 increased binding of the envelope protein to
SR-BI (Fig. 2E). Among the four stretch deletion mutants (1–
13, 16–24, five key, and HVR1), only deletion of the entire
HVR1 showed enhanced CD81 binding activity compared with
the prototype protein (Fig. 2F).
FIGURE2.Regions spanningaa1–13and16–24aredispensable forHCVppcell entry.A,293Tcellswere co-transfectedwith lentivirus transfer plasmid,HIV
capsidplasmid, Revplasmid, andplasmidsencodingH77envelopeglycoproteinswithdeletion inHVR1. Pseudoparticlesnormalized toequal quantities ofHCV
E2 and HIV Gag proteins were used to infect Huh7.5 target cells, and infectivity was determined in the presence or absence of human HDL at a concentration
of 6 g/ml. The results are expressed as percentage of infectivity of wild-type H77. 5 key refers to envelope mutants preserving only aa 14, 15. and 25–27 in
HVR1. Results are themeans S.D. of four independent experiments. *, p 0.001; **, p 0.01 compared with H77 prototype pseudoparticles in the absence
of HDL. B, pseudoparticles in culture media of 293T cells were pelleted through 20% sucrose cushions, and HCV envelope proteins and HIV capsid protein in
pseudoparticle preparationswere assayed byWestern blotting. C, envelope expression plasmids containing variousmutationswere used to generate HCVpp,
and the infectivity of the respective pseudoparticles wasmeasured as described above. Co-transfection of 293T cells devoid of HCV envelope proteins (env)
plasmidwasperformedas anegative control. C3A represents a construct inwhichall three residues locatedatpositions 25–27were replacedwith alanine.Data
are means  S.D. of three independent experiments. D, CHO cells were infected with lentivirus containing human SR-BI cDNA or CD81 cDNA or empty
lentivirus, respectively, and the expression of human SR-BI and CD81was determined by flow cytometry withmAb to CD81 ormouse polyclonal antibodies to
SR-BI. CHOcells infectedwith empty lentiviruswereusedas anegative control. E, crudeextracts of 293T cells transfectedwithHCVenvelopeprotein expression
plasmidwere normalized byGNA capture ELISA, and the extracts containing equivalent amounts of prototype ormutant E2 proteinwere used tomeasure cell
surface-associated SR-BI binding using a FACS-based assay. The extract of mock plasmid-transfected 293T cells that contained equivalent amounts of cellular
protein as the E2 protein containing extract was used as a negative control (env). The binding activity is expressed as the percentage of MFI relative to that
of H77 prototype envelope proteins. Results are the means  S.D. of three independent experiments. *, p  0.05 compared with H77 prototype envelope
proteins. F, binding of mutant E2 proteins to cell surface-associated CD81 was measured using a FACS-based assay. Results are the means  S.D. of three
independent experiments. *, p 0.05 compared with H77 prototype envelope proteins.
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HVR1 Residues 16–24 Contain a Neutralization Epitope—
To identify neutralization epitopes in HVR1, rabbits were
immunized with fusion proteins containing TRX and H77
HVR1, aa 1–13 (N13), aa 8–20 (M13), or aa 14–27 (C14) (Fig.
3A), and IgG fractions from the resulting sera were character-
ized for their ability to recognize epitopes inHVR1.As shown in
Fig. 3B, serum IgG purified from a rabbit immunized with the
TRX-HVR1 fusion protein (RH104) bound to the 1–13 pro-
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tein as well as to the unmodified envelope protein. However, it
did not bind to 16–24 (Fig. 3B). Similarly, IgG from rabbits
immunized with TRX-C14 (RC201 and RC202) recognized the
1–13 and prototype proteins but not the16–24 protein. IgG
from rabbits immunized with TRX-N13 fusion protein (RN203
and RN204) or with the TRX-M13 protein (RM205) was unable
to recognize the prototype or any one of the deletion mutant
envelope proteins. IgG from rabbit RH104 and RC202 did not
bind the 25 protein but bound the 15 protein, whereas IgG
from rabbit RC201 was unable to bind 15, but it could bind to
25 (Fig. 3B). The IgG preparations (20–500 g/ml) had simi-
lar binding profiles. The data suggest that aa 16–24 contain an
antigenic epitope, and epitope recognition at flanking residues
may differ among different immunized animals. The neutraliz-
ing activity of these antibodies for HCVpp was determined. As
shown in Fig. 3C, both anti-HVR1 (RH104) and anti-C14 anti-
bodies (RC201) efficiently neutralized the prototype and1–13
pseudoparticles. However, these antibodies did not affect the
infectivity of 16–24 or five key pseudoparticles. As expected,
IgG from TRX-N13-immunized rabbit (RN203) did not neu-
tralize any of the indicated pseudoparticles.
Similar results were obtained with immune sera collected
from mice that received HBsAg and H77 HVR1 fusion gene
vaccination (Fig. 3D). All 12 serum samples recognized parental
E1E2 and 1–13 proteins, but none could recognize 16–24
proteins. The residue at position 15 was involved in an anti-
genic epitope in fourmice (NS2, NS6, SC3, and SC4) and that at
position 25 was involved in antigenic epitope in two mice (NS5
and SC6). Both aa 15 and 25 were involved in the antigenic
epitope in mouse NS3.
Stretch Comprising HVR1 Amino Acids 16–24 Inhibits Anti-
body Neutralization in the Presence of HDL—To investigate
whether aa 16–24 inHVR1 contains a neutralization epitope in
other HCV isolates, plasmids that express chimeric H77-Con1
and Con1-H77 envelope proteins were constructed. In these
constructs, the 16–24-aa encoding sequence of HVR1 in H77
was swapped with the corresponding sequence of Con1 isolate
(1b subtype) and vice versa (Fig. 4A). The amino acid sequences
of parental and chimeric HVR1 are shown in Fig. 4B. The chi-
meric protein expressed in 293T cells could bind to SR-BI and
CD81 at a similar efficiency as that shown by prototype protein
(data not shown). Rabbit anti-H77 HVR1 IgG could bind to the
H77 prototype and Con1-H77 chimeric proteins, whereas rab-
bit anti-Con1 HVR1 IgG could bind to Con1 prototype and
H77-Con1 chimeric proteins (Fig. 4C). The H77-Con1 and
Con1-H77 chimeric pseudoparticles demonstrated about 78
and 83% of the infectivity that was observed for the respective
parental pseudoparticles in media devoid of HDL (Fig. 4D).
Deletion of aa 16–24 in Con1 HVR1 did not affect pseudopar-
ticle infectivity, but it ablated the ability of HDL to stimulate
HCVpp infection, and the 16–24-aa stretch in theH77 or Con1
HVR1 isolates restored the pseudoparticle response to HDL
when transferred into heterogeneous envelope proteins (Fig.
4D). In neutralization assays with HVR1 antibodies, the infec-
tivity ofH77-Con1 chimeric viruswas not inhibited by antibod-
ies to H77HVR1, whereas it was markedly reduced by antibod-
ies to Con1 HVR1 (Fig. 4E). Antibodies to Con1 HVR1
efficiently neutralized both autologous Con1 and chimeric
H77-Con1 pseudoparticles, but it did not inhibit the infectivity
of autologous pseudoparticles with 16–24-aa deletion (Fig. 4E).
H77 E2-specificmAbH48 is a conformation-dependent neu-
tralizing antibody that disturbs interaction betweenHCVenve-
lope protein and the HCV secondary receptor CD81 (49). This
antibody efficiently reduced bothH77 andH77-Con1 pseudop-
article infectivity, but the neutralizing activity was notably
inhibited when HDL was present (Fig. 4F). For pseudoparticles
with a 16–24-aa deletion, the neutralizing activity of mAb H48
was not affected by HDL (Fig. 4F). Moreover, in the presence of
HDL, neutralization of H77 and Con1 pseudoparticles with
deletion of aa 16–24 by IgGpreparations from three individuals
chronically infected with HCV (1b genotype) was much more
robust than that seen for the prototype pseudoparticles (Fig.
4G). To identify key residues in aa 16–24 that confer HCVpp
resistance to E2 antibodies, HCVpp harboring single residue
deletions in aa 16–24 were used in neutralization assay. In the
presence ofHDL, removal of any residue significantly increased
pseudoparticle neutralization by mAb H48, and pseudopar-
ticles with deletion of the entire 16–24-aa neutralization
epitope showedmaximum sensitivity to this antibody (Fig. 4H).
Region across Amino Acids 16–24 Plays an Important Role in
Envelope-Heparan Binding—The glycosaminoglycan heparan
sulfate acts as a primary docking site for HCV, andHVR1 is one
of the important viral determinants for HCV-heparan interac-
tion (23, 59). To identify potential peptide fragments involved
in heparan binding, the binding of envelope protein to heparan
and the inhibition of envelope-heparan binding by HVR1 anti-
bodies were assayed by ELISA. Equal quantities of envelope
proteins from 293T cell extracts were subjected to heparan
binding analysis (Fig. 5A). Deletion of the entire HVR1 or of
residues at the HVR1 C terminus markedly decreased enve-
lope-heparan binding; however, deletion of aa 1–13 did not
affect envelope-heparan binding (Fig. 5, B and C). Preincuba-
tion of unmodified E1E2 and 1–13 proteins with HVR1 anti-
body (Fig. 5B) or C14 antibody (Fig. 5C) resulted in a concen-
FIGURE3.Regioncomprisingaa16–24containsaneutralizationepitope.A, aminoacid sequenceofH77HVR1and thepeptide expressedas a thioredoxin-
peptide fusionprotein thatwasused for rabbit immunization.B,HCVenvelopeproteins in lysatesof 293T cells transfectedwith apanel of plasmidswere coated
ontomicroplates usingGNA, and then the binding of the envelope proteins to IgGpurified from six rabbits immunizedwith TRX-HVR1 peptide fusion proteins
was measured by ELISA. The anti-HVR1 peptide IgG preparations were used at a concentration of 100 g/ml. Conformation-dependent anti-E2 monoclonal
antibody H53 (1:1,000 dilution) was used to assay E2 protein in cell lysate. The lysate of empty plasmid-transfected 293T cells was used as a negative control
(Mock). C, similar inputs of various viral particles normalized for HCV E2 and HIV Gag proteins were preincubated with IgG (100 g/ml) fractionated from sera
collected from immunizedorunimmunized rabbits at RT for 30minbefore infectionofHuh7.5 target cells. The infectivity ofHCVppwasdeterminedafter 3days
asdescribedabove. VSV-GPwasusedas control. Results are themeansS.D. of four independent experiments.D, total of 12micewere immunizedwithHBsAg
and H77 HVR1 fusion gene expression plasmids. Six mice (NS1–NS6) received HVR1-HBsAg expression plasmid and other six mice (SC1–SC6) received HBsAg-
HVR1 expression plasmid. Themouse serawere collected at 2weeks after the third immunization andwere used as anti-HVR1 antibodies in ELISA. The data are
the values formouse sera at a dilution of 1:500. ThemAbH53diluted at 1:1,000was used as control to assay envelopeprotein capturedontomicroplates.Mock
means the lysate of 293T cells transfected with the empty vector.
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tration-dependent inhibition of envelope-heparan binding. In
addition, neither IgG from rabbits immunized with TRX-N13
nor that from rabbits immunizedwithTRX-M13 fusion protein
could inhibitHCVenvelope-heparan binding (data not shown).
These data suggest that the 16–24-aa region plays an important
role in mediating the interaction of HCV envelope protein to
heparan.
Combined Mutation in HVR1 N Terminus Enhances HCVpp
Infectivity and Reduces the Neutralizing Activity of HVR1
Antibodies—Having seen that the region across residues 1–13
is not necessary for HCVpp infectivity, experiments were per-
formed to investigate the potential significance of mutation in
this region. The envelope sequence of theH77 isolate used here
corresponds to that deposited in GenBankTM under accession
number AF011752. Another envelope sequence with accession
number AF011753 was obtained from the same patient at the
same time. The clones differ in two residues. In AF011752, a
serine and a histidine are located at positions 8 and 11 inHVR1,
whereas the residues at corresponding positions in AF011753
are, respectively, asparagine and arginine (Fig. 6A). To deter-
mine whether two point mutations are functionally significant,
Ser-8 andHis-11 in the original H77 sequence were replaced by
an Asn and an Arg (S8N and H11R), and the infectivity of the
corresponding pseudoparticles was determined. As shown in
FIGURE4.StretchacrossHVR1aa16–24protectsHCVppagainst neutralization in thepresenceofHDL.A, two chimericHCVenvelopeprotein expression
plasmidswere constructed. InH77-Con1plasmid,HVR116–24-aa stretch inH77envelopebackbonewas swapped for the corresponding sequence in theCon1
isolate (1b subtype). In Con1-H77plasmid, HVR1 16–24-aa stretch in theCon1 envelopebackbonewas swapped for that of H77HVR1. B, amino acid sequences
of parental and chimericHVR1.C,HCVenvelopeproteins in lysates of 293T cells transfectedwithH77, Con1, or chimeric plasmidswere coatedontomicroplates
using GNA, and then the binding of the envelope proteins to IgG fractionated from sera of rabbits immunized with TRX-H77 HVR1 or TRX-Con1 HVR1 (100
g/ml) was analyzed by ELISA. The lysate of mock-transfected 293T cells was used as a control. Results are the means of three independent experiments. D,
pseudoparticleswere prepared as described. After filtration, equal volumes of culture supernatantswere used to infectHuh7.5 cells in the absenceor presence
of HDL (6g/ml), and infectivity was determined 3 days later. Results are themeans S.D. of three independent experiments. *, p 0.001. E, pseudoparticles
bearing prototype and chimeric envelope proteins were normalized to equal infectivity levels and used to assess the neutralizing activity of rabbit antibodies
to H77 HVR1 or Con1 HVR1. VSV-GP was used as a control. Results are the means S.D. of four independent experiments with antibodies at a concentration
of 100g/ml. F,pseudoparticles normalized to equal infectivitywere incubated (30min at RT)with E2mAbH48 at the indicated concentrations in the absence
or presence of 6 g/ml HDL and then added to Huh7.5 cells. Infectivity was determined 3 days later. Data are the means  S.D. of three independent
experiments. *, p 0.001.G, IgG preparations (A–C) were fractionated from sera of three confirmedHCV-infected individuals (positive for serumHCV RNA and
anti-HCV antibodies) using protein A/G column. H77 and Con1 pseudoparticles (prototype and aa 16–24 deleted) normalized for equal infectivity were
incubated with IgG preparations at a concentration of 100 g/ml in presence of 6 g/ml HDL for 30 min at RT and then added to Huh7.5 cells. Infectivity was
determined after 3 days. Data are themeans S.D. of three independent experiments. *, p 0.001.H, pseudoparticles bearing prototype or various envelope
proteins deletion mutants were normalized to equal infectivity and then used to assess the neutralization activity of E2 mAb H48 at a concentration of 0.5
g/ml in presence of 6 g/ml HDL as described above. Data are the means S.D. of three independent experiments. *, p 0.05; **, p 0.01; ***, p 0.001
compared with H77 prototype pseudoparticles.
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Fig. 6B, the double mutant showed a 1.9-fold increase in
HCVpp infectivity, whereas both single residue mutations did
not affect pseudoparticles infectivity. Examination of the bind-
ing potential of the mutant envelope proteins to SR-BI and
CD81 indicated that the double mutant but not the single
mutants had a much higher binding efficiency to SR-BI than
that of prototype E2 protein (Fig. 6C). However, theCD81bind-
ing profiles of the three mutants were similar to that of proto-
type E2 protein (Fig. 6D).
Pseudoparticles normalized with equivalent particles or
infectivity were used to analyze the effect of the double muta-
tions on HVR1 antibody neutralization. When anti-HVR1 was
preincubated with equal amounts of pseudoparticles (by assay-
ing HCV envelope and HIV Gag proteins incorporated into
pseudoparticles), the neutralization of the pseudoparticles con-
taining double mutations was less efficient than that of the
unmodified pseudoparticles (Fig. 6E, left panel). When pseu-
doparticles with equal infectivity (by assaying pseudoparticles
infectivity using Huh7.5 cells as target cells) were used, HVR1
antibodies showed similar neutralizing activities to both pseu-
doparticles (Fig. 6E, right panel).
HCVcc Model Confirms the Functional Impact of the Identi-
fied HVR1 Regions on HCV Infection—To examine the rele-
vance of these HVR1 regions in authentic HCV particles, dele-
tions were introduced into H77/JFH1 chimeric cDNA plasmid,
and the transcribed RNAs were used to transfect Huh7.5 cells
or CD81-deficient Huh7 cells by electroporation. Intracellular
and extracellular core protein levelswere determined byELISA.
At 24 h post-transfection, the amount of accumulated core in
Huh7.5 cells or the culture medium was similar among the dif-
ferent transfectants (Fig. 7A, left panel). Removal of aa 13–27 or
the entire HVR1 led to a marked decrease in the levels of both
intracellular and extracellular core proteinwhen assayed at 48 h
post-transfection, but core protein levels were not affected by
the removal of aa 1–13 or 16–24 (Fig. 7A, right panel). To
exclude the effect caused by infection of progeny virus, the core
protein assays were done with CD81-deficient Huh7 cells,
which cannot not be infected by freeHCVcc virions but support
HCV RNA replication (55). When assayed at 24 or 48 h post-
transfection, intracellular and extracellular core protein levels
for all the CD81-deficient Huh7 transfectants were comparable
(Fig. 7B).
Finally, we assayed the infectivity of Huh7.5 culture superna-
tants at day 5 post-transfection. As shown in Fig. 7C, when
infection was done in the absence of human HDL, deletion of
the entire HVR1 or the C-terminal 15-aa residues (13–27)
decreased the infectivity below the assay detection limit of 20
FFU/ml, although deletion of aa 1–13 (1–13) decreased the
infectious titers to about 76% of the parental virus titers. Dele-
tion of aa 16–24 (16–24) did not affect infectivity with
detected virus titers similar to those of the parental virus (Fig.
7C). Furthermore, just as in the case of the pseudoparticle
model, both the HDL-mediated infectivity enhancement and
the HVR1 antibody neutralizing potentials were dependent on
the 16–24-aa region (Fig. 7, C andD). The HCVcc neutralizing
potential of the mAb H48 was inhibited by HDL, and it is clear
that aa 16–24 conferred virus resistance to this antibody (Fig.
7E). HCVcc with deletions of single residues within aa 16–24
showed comparable infectivity to that seen for the prototype
virus (data not shown). As seen for HCVpp, deletion of any
residue within aa 16–24 up-regulated HCVcc sensitivity to
FIGURE 5. Stretch across HVR1 aa 16–24 plays an important role in the
binding of HCV envelope proteins to heparan. HCV envelope proteins in
293T cells extracts were normalized by GNA capture ELISA, and equal quan-
tities were preincubated with IgG from sera of rabbits immunized with TRX-
HVR1 fusion protein for 1 h at RT. Subsequently, envelope protein/antibody
mixtures were added to ELISA plates coated with heparan. Heparan-bound
E2wasdetectedusingmAbH53.Data are shownasmeanOD S.D. obtained
from a representative experiment performed in triplicate. The extract from
mock plasmid-transfected 293T cells that contained equivalent amounts of
total cellular protein as the E2 protein containing extracts was used as a neg-
ative control (Mock). A, assay of HCV envelope protein in the extracts of plas-
mid transfected 293T cells by GNA capture ELISA. B, inhibition of envelope-
heparan binding by IgG from TRX-HVR1 immunized rabbit RH104. C,
inhibitionof envelope-heparanbindingby IgG fromTRX-C14 immunized rab-
bit RC202.
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mAb H48, and HCVcc with deletion of aa 16–24 were most
easily neutralized by mAb H48 (Fig. 7F).
DISCUSSION
In this study, we identified three independent functional
regions in the HVR1 component of the H77 isolate. The data
herein show the relevance of thesemicrodomains formediating
virus cell entry, antibody-mediated neutralization, and immune
evasion.
Using deletion mutagenesis and function analyses, we found
that five aa residues (Ala-14, Gly-15, Lys-25, Gln-26, and Asn-
27)within theHVR1of theH77 isolate play a key role inHCVpp
entry. Deletion of any one of these five residues caused a signif-
icant loss of pseudoparticle infectivity, whereas deletion of any
residue in other regions had only a slight effect on their infec-
tivity. Despite the requirement of these five residues forHCVpp
infectivity, a single residue substitution at each one of these five
positions only moderately decreased the pseudoparticle infec-
tivity. However, the combined mutation of Ala-14 and Gly-15
(A14G/G15A) or Lys-25, Gln-26, and Asn-27 (C3A) decreased
HCVpp infectivity to about 40 and 25%, respectively. The
importance of these five residues is further supported by the
findings that deletion of aa 1–13 (1–13) attenuated HCVpp
infectivity by only about 20%, whereas deletion of aa 16–24
(16–24) did not decrease but instead increased the infectivity
of the resulting HCVpp by about 40%. These findings extend a
previous report that the basic residue at position 25 in H77
HVR1 is important for the infectivity of HCVpp (42), but they
differ from that report in that they suggest that the basic resi-
dues at positions 3 and 11 are dispensable for HCV cell entry.
HCV envelope proteins are heavily glycosylated, and some of
the glycans have been shown to play an essential role in protein
folding and HCV entry (42, 60). Bankwitz et al. (34) recently
reported that deletion of HVR1 does not influence the glycosyl-
ation of the HCV envelope. Because HVR1 does not contain
glycosylation sites, variable infectivity of HCVpp carrying
HVR1 deletions cannot be due to the defective glycosylation of
envelope proteins. It has been suggested that there is a complex
interplay between HVR1 and the SR-BI and CD81 receptors
(34, 58). We found that binding of envelope mutants to SR-BI
directly correlates with the cell entry efficiency of the corre-
sponding pseudoparticles, suggesting that the five identified
FIGURE 6. Residues within HVR1 N terminus modulate HCVpp infectivity. A, amino acid sequences of H77 HVR1 and its mutants. B, plasmids encoding
H77/S8NH11R, H77/S8N, and H77/H11R cDNAs were used to generate HCVpp that were used in infectivity assays. Results are expressed as the mean
percentage of infectivity relative to that of the H77 prototype  S.D. of five independent experiments. *, p  0.001; **, p 	 0.05 relative to H77 prototype
pseudoparticles. C, binding of E2 protein containing S8N and/or H11R mutation to cell surface-associated SR-BI was measured using a FACS-based assay.
Results aremeans S.D. of three independent experiments. *,p0.001; **,p	0.05 comparedwithH77prototypeenvelopeproteins.D,bindingof E2protein
containing S8N and/or H11R mutation with cell surface-associated CD81 was measured using a FACS-based assay. Results are means  S.D. of three inde-
pendent experiments. *, p	 0.05 relative toH77prototype envelope proteins. E,pseudoparticles bearing theH77prototype or theH77/S8NH11Rmutation
were normalized to equal quantities of particles (by assaying HCV envelope proteins and HIV Gag protein incorporated into pseudoparticles) (left panel) or to
equal infectivity (right panel) and then treated with H77 HVR1 antibodies at indicated concentrations. The infectivity was determined 3 days after infection.
VSV-GP was used as a control. Data are themeans S.D. of quadruple measurements and are from one representative out of four independent experiments.
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FIGURE 7. Effect of HVR1 deletions on infectivity of HCVcc and neutralization by HVR1 and E2 antibodies. A, Huh7.5 cells were transfected with
transcribedHJ3/QL chimeric genomic RNAor eachof the indicateddeletionmutants. HCV coreprotein in transfectedHuh7.5 cells and culture supernatantwas
determined at 24 h (left panel) and 48 h (right panel) post-transfection using a commercial ELISA kit. The cell lysate or culture medium of sham-transfected
Huh7.5 cells devoid of transcribed RNA were used as negative control (Mock). Results are the means  S.D. of three independent transfection and ELISA
experiments. *, p	 0.05; **, p 0.001 relative to intracellular or extracellular core protein of Huh7.5 cells transfected with H77-JFH1 prototype genomic RNA.
B, CD81-deficient Huh7 cells were transfected with transcribed HJ3/QL chimeric genomic RNA, and intracellular and extracellular HCV core protein was
determined at 24 h (left panel) and 48 h (right panel) as described. *, p 	 0.05 relative to intracellular or extracellular core protein of cells transfected with
H77-JFH1prototype genomic RNA.C,Huh7.5 cells were transfectedwith transcribedHJ3/QL chimeric genomic RNAor each of the indicated deletionmutants.
The culture supernatants collected at day 5 post-transfection were incubated with Huh7.5 cells in the presence or absence of 6 g/ml HDL, and HCVcc
infectivity was determined by FFU assays 2 days later. Control represents the infectivity in supernatants of sham-transfected Huh7.5 cells. The cutoff value of
the assay was 20 FFU/ml. Results are themeans S.D. of three independent transfection and infection experiments. *, p 0.001.D,HCVcc supernatants were
concentrated 5-fold by ultrafiltration and normalized to an equal infectivity of 2,000 FFU/ml. Virus stock (100l) was preincubated with total IgG fractionated
from sera collected from rabbits immunizedwith TRX fused toH77 or Con1HVR1 peptide (100g/ml) and added toHuh7.5 cells in 96-well plates. After 2 days,
the cells were immunostained for NS5A, and virus neutralization was expressed as percent inhibition of infectious titers relative to antibody-free medium.
Results are expressed as means  S.D. of quadruplicate measurements and are representative of three independent experiments. E, virus stock with a
normalized infectivity of 2000 FFU/ml (100l) was incubated (30min at RT)with E2mAbH48at indicated concentrations in the absenceor presenceof 6g/ml
HDL and added to Huh7.5 cells in 96-well plates. After 2 days, the cells were immunostained for NS5A, and virus neutralization was calculated. Results are the
means  S.D. of quadruplicate measurements and are representative of three independent experiments. *, p  0.01; **, p  0.001. F, normalized HCVcc
harboring deletion mutations in the HVR1 neutralization epitope were used to assess the neutralization activity of E2 mAb H48 at a concentration of 5g/ml
in thepresence of 6g/mlHDL as described above. Data are themeans S.D. of three independent experiments. *,p 0.01; **,p 0.001 relative toH77-JFH1
HCVcc.
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key residues mediate entry predominantly through their ability
to regulate interaction between envelope proteins and SR-BI.
Because of the poor conservation of these five residues in dif-
ferent HCV isolates, and the limited effect that their individual
mutation has onHCVpp infectivity, we cannot exclude the pos-
sibility that their role in interaction with SR-BI is indirect. It is
possible that deletion of residues within HVR1 could create
local conformational changes or affect the interaction between
HVR1 and other domains outside of HVR1. In this case, these
residues may cooperate to regulate the E2-SR-BI interaction
through modulating the triaxial conformation of the SR-BI
binding domain in the E2 protein. Deletion of aa 16–24
enhanced the E2-SR-BI interaction and pseudoparticle infec-
tivity, indicating that this region may increase the steric hin-
drance around key residues of the SR-BI binding domain and in
turn can interfere with the accessibility of these residues to
SR-BI.
To identify antigenic epitopes within HVR1, HVR1-specific
antibodies were raised by immunizing rabbits with thiore-
doxin-HVR1 peptide fusion proteins. At least in our experi-
mental conditions, the N-terminal 13 amino acids and middle
13 amino acids do not contain a neutralization epitope. It is
worth noting that non-neutralizingmonoclonal antibodies rec-
ognizing the N terminus of HVR1 have been described (61),
suggesting that the region across the N-terminal 13 residues
may comprise an epitope that interacts with non-neutralizing
antibodies. The failure to generate antibodies against this
region in our immunization experiments suggests that this
epitope may need to be recognized within the context of E2 to
induce an appropriate immune response.
Mapping of the epitopes that are recognized by antibodies
elicited during a natural infection to HVR1 requires sera from
HCV-infected patients. However, our data demonstrate that a
neutralizing epitope in H77 HVR1 is located in a region across
aa 16–24. TheE2 protein deleted inHVR1 aa 16–24was unable
to bind antibodies from any immunized rabbit, and the pres-
ence of aa 16–24 was required for HCVpp neutralization by
HVR1 antibodies. The data indicate that the region spanning aa
16–24 includes a neutralization epitope, a conclusion that is
further supported by the results of the antibody binding assay
using sera frommice vaccinated with HBsAg and HVR1 fusion
gene DNA vaccines. To our knowledge, there are no current
reports about the definite mapping of neutralizing epitopes in
HVR1, although some reports suggested that the residues at the
C terminus are important for inducing immune responses (62–
64). Vieyres et al. (65) reported that the neutralizing antibodies
induced by immunization with H77c and Gla HVR1 peptides
reacted with the C-terminal portion of HVR1, but the exact
epitopes were not mapped. The infectivity and neutralization
assays using H77-Con1 chimeric pseudoparticles and Con1
pseudoparticles with deletions in the HVR1 aa 16–24 suggest
that aa 16–24 also constitute a sole neutralization epitope in
Con1 HVR1. Considering the important role played by this
region in eliciting a humoral response, it may be reasonable to
suggest that the residues in this region may have a higher vari-
ation frequency than those in other regions of HVR1. Support-
ing this interpretation, themutations inHVR1mainly occurred
in this region, when comparing isolate H77 that represents
HCV in the acute-phase plasma and H90, which was isolated
from a chronic-phase plasma obtained from the same patient
13 years after the acute infection (66).
HDL enhances HCV infectivity and inhibits the neutralizing
activity of antibodies against the E2 protein by involving the
lipid-transfer function of SR-BI, which is the receptor for both
HDL andHCV (33, 38, 39). It was demonstrated that apoC-I, an
exchangeable apolipoprotein that predominantly resides in
HDL, specifically enhances HCV infectivity and increases the
rates of fusion between viral and target membranes via a direct
interaction with HVR1 (39). Our data indicate that different
amino acid stretches in HVR1 are responsible for E2-SR-BI
interaction and infection enhancement byHDL. In theH77 and
Con1 HVR1, the 16–24-aa stretch acts as the exact functional
region for HDL interplay, with the nine residues in this region
cooperating to reach maximal activity. Indeed, the 16–24-aa
stretch robustly decreased the neutralizing activity of the HCV
E2 mAb H48 and IgG from HCV-infected individuals in the
presence of HDL. This observation may account for the signif-
icance of the neutralizing epitope for HCV survival in vivo,
although it is dispensable for HCV entry. Together with a
recent report that HCVcc that lack HVR1 have fewer particles
with low density and are more prone to neutralization by
E2-specific monoclonal antibodies and patient sera (34), our
data suggest that aa 16–24 in HVR1 may be involved in the
association of lipoprotein with HCV particles in vivo and in
turn may modulate HCV infectivity and immune evasion.
Interaction with glycosaminoglycan heparan sulfate is con-
sidered to be the first event of HCV cell attachment that repre-
sents an important step for the initiation of HCV infection.
Some studies have identifiedHVR1 as a key component ofHCV
interaction with heparan (23, 59). In this study, we provide evi-
dence that the neutralization epitope at aa 16–24 plays an
important role in HCV envelope-heparan binding. Removal of
this region led tomarkedly decreased heparan binding by enve-
lope protein, but it did not impede HCVpp infectivity, which
may be due to increased SR-BI binding of envelope protein.Our
data also substantiate that HVR1 antibodies neutralize HCV
infection partly by disturbing the envelope-heparan interaction
(23), because the envelope binding to heparan was inhibited by
antibodies to the 16–24-aa region.
There are two residue differences (at HVR1 positions 8 and
11) between the sequence used for functional mapping (Gen-
BankTM accession number AF011752) and another sequence
obtained from the same patient at the same time (GenBankTM
accession number AF011753). Replacement of both residues in
the former HVR1 with those in the latter HVR1 enhanced
HCVpp infectivity by 1.9-fold. The neutralizing efficiency of
anti-HVR1 antibody to an equivalent amount of pseudopar-
ticles harboring dual mutations in HVR1 was markedly
decreased. This may be related to enhanced SR-BI binding of
the E2 protein carrying the double mutation. Collectively, the
data suggest that the N-terminal region of HVR1 regulates the
infectivity of the virus and in turn protects it from neutralizing
antibodies directed to the epitopewithin theHVR1C terminus.
Unlike classical immune evasion through mutation in a neu-
tralization epitope, mutations in the HVR1 N terminus may
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represent an alternative strategy that protectsHCV fromHVR1
neutralizing antibodies.
Cell culture- and serum-derivedHCV is associatedwith lipo-
proteins, which contributes to the heterogeneous density of
HCV particles (67). The interaction with lipoproteins is impor-
tant for HCV infectivity (68). HCVppwas created in 293T cells,
a human embryonic kidney cell line that is unlikely to produce
lipoprotein, suggesting that this model may not fully recapitu-
late the infectivity of authentic HCV particles. However, we
confirmed the findings in the HCVcc system, the state-of-the-
art model for HCV infection. Intracellular and extracellular
core protein levels could be used as an indicator of RNA repli-
cation and virus production (34, 35, 53). The core assay of
Huh7.5 cells transfected with HCV genomic RNA at an early
stage post-transfection (24 h) indicated that removal of the
entire HVR1 or amino acid stretches in the HVR1 N terminus
does not affect HCV RNA replication and virus release. The
decreased intracellular and extracellular core protein levels at
48 h post-transfection caused by deletion of the entire HVR1 or
aa 13–27 are likely due to impaired virus infectivity. Indeed,
CD81-deficientHuh7 cells transfectedwith RNAdeleted at dif-
ferent HVR1 sites produced similar amounts of core protein at
24 or 48 h post-transfection.
Kawaguchi et al. (69) have recently reported that a quasispe-
cies could be reproduced in vitro from plasma collected in 1977
frompatientH (the same patient investigated herein), but serial
passage of the quasispecies resulted in replacement of the ini-
tially dominant species with a new HVR1 species. Together
with our data, this may be due to the evolution of HVR1 func-
tional microdomains that increase virus cell entry in culture.
Consistent with our findings for the H77 and Con1 isolates,
the residues at the C terminus in the HVR1 of the J6 isolate (2a
genotype) are important for HCVpp infectivity, whereas those
located at the N terminus are nonessential (data not shown).
Furthermore, residues across position 16–24 were dispensable
for HCVpp infectivity and served as a neutralization epitope in
theHVR1 of the J6 isolates, and this peptide is indispensable for
enhancement of HCV infectivity by HDL. These data suggest
that our observation is also relevant for other HCV isolates and
genotypes, and it is possible that HVR1 evolves in a similar
manner inside a given genotype to optimize both cell entry and
immune evasion.
In conclusion, our data indicate that the HCV HVR1 con-
tains independent functional microdomains. For the H77
HVR1, the first microdomain includes five residues at positions
14, 15, and 25–27 and plays a key role in binding of the HCV
envelope protein to the SR-BI receptor. Any residue in this
microdomain is indispensable for HCV cell entry. The nine
residues across positions 16–24 constitute the second
microdomain, which contains the neutralization epitope and
appears to be dispensable for cell entry. This microdomain is
necessary for the enhancement of HCV infectivity by HDL and
confers HCV resistance to neutralizing antibodies targeted to
an epitope outside of HVR1. It also plays an important role in
HCV envelope-heparan binding. The third HVR1 microdo-
main across aa 1–13 is dispensable forHCVcell entry, but it can
affect HCV infectivity by modulating the binding of the enve-
lope protein to SR-BI.Mutations in thismicrodomainmay con-
ferHCV resistance toHVR1 antibodies. These findings provide
novel insights into our understanding of the role played by
HVR1 in mediating HCV cell entry, immune evasion, and anti-
body-mediated neutralization and will thus contribute to the
development of entry inhibitors or a protective vaccine that
targets the interaction between HVR1 and cell entry factors.
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